children |
25 |
covid-19 |
16 |
sars-cov-2 |
13 |
adolescents |
12 |
convalescence |
12 |
sars-cov-2 rbd igg |
12 |
t cell response |
12 |
immunotherapy |
11 |
vaccine |
11 |
allergy |
10 |
asparaginase |
10 |
chinese |
10 |
human leukocyte antigens |
10 |
hypersensitivity |
10 |
nk cells |
9 |
antimicrobial resistance |
8 |
bacteria |
8 |
bnt162b2 mrna covid-19 vaccines |
8 |
hypercytokinemia |
8 |
infants |
8 |
inflammation |
8 |
innate immunity |
8 |
kir genetics |
8 |
meningitis |
8 |
neonates |
8 |
translation to patients |
8 |
vaccine-related myocarditis |
8 |
adolescent |
7 |
coronavac |
7 |
omicron |
7 |
extracellular vesicle |
6 |
head and neck neoplasms |
6 |
radiotherapy |
6 |
t-lymphocytes |
6 |
tumor |
6 |
tumor microenvironment |
6 |
γδ t cells |
6 |
γδ-t cells |
6 |
ampk |
5 |
glucose metabolism |
5 |
lactate |
5 |
t2dm |
5 |
tumor surveillance |
5 |
pediatrics |
4 |
allogeneic transplantation |
3 |
bone marrow transplantation |
3 |
hematopoietic stem cell transplantation |
3 |
immune reconstitution |
3 |
infections |
3 |
acute lymphoblastic leukemia |
2 |
acute myeloid leukemia |
2 |
adenovirus |
2 |
allogeneic bmt |
2 |
allogeneic bone marrow transplantation |
2 |
aml |
2 |
aplastic anemia |
2 |
autologous transplantation |
2 |
bone marrow transplant |
2 |
cancer |
2 |
cd34 selection |
2 |
child |
2 |
childhood |
2 |
childhood leukemia |
2 |
graft-versus-host disease |
2 |
haploidentical |
2 |
hematopoietic stem cell |
2 |
hemorrhagic cystitis |
2 |
high-dose chemotherapy |
2 |
langerhans cell histiocytosis |
2 |
leukemia |
2 |
myelodysplastic syndrome |
2 |
natural killer cells |
2 |
neuroblastoma |
2 |
oncology |
2 |
paediatric |
2 |
pediatric |
2 |
relapse |
2 |
second malignancy |
2 |
stem cell transplantation |
2 |
survival |
2 |
transplantation |
2 |
abdominal |
1 |
acute gvhd |
1 |
acute lymphoblastic leukaemia |
1 |
acute myeloid leukaemia |
1 |
adoptive cell therapy |
1 |
adoptive immunotherapy |
1 |
alloegenic hematopoietic cell transplantation |
1 |
allogeneic |
1 |
allogeneic hematopoietic stem cell transplantation |
1 |
allogeneic hsct |
1 |
allogeneic stem cell transplantation |
1 |
antithymocyte globulin |
1 |
aplastic anemia engraftment |
1 |
asymptomatic |
1 |
atmp |
1 |
atovaquone |
1 |
autogvhd |
1 |
autologous |
1 |
autologous bmt |
1 |
autologous hsct |
1 |
b cells |
1 |
baboon envelope |
1 |
biological assay |
1 |
biological assays |
1 |
bk virus |
1 |
bmt immunology |
1 |
bone marrow metastasis |
1 |
brain necrosis |
1 |
bronchoalveolar lavage |
1 |
bronchoscopy |
1 |
car |
1 |
caregiver preferences |
1 |
cd34 |
1 |
cd34 cells + |
1 |
cd34 progenitors |
1 |
cd45ra depletion |
1 |
cd5 b cells + |
1 |
cell therapy |
1 |
cellular therapy |
1 |
cendritic cell |
1 |
childhood acute lymphoblastic leukemia |
1 |
childhood aml |
1 |
chimera assays |
1 |
cidofovir |
1 |
circulating tumor cells |
1 |
clearance |
1 |
clinical nk cell studies |
1 |
clinical trial |
1 |
clinimacs |
1 |
clofarabine |
1 |
competing risk |
1 |
complications |
1 |
computed tomography |
1 |
computed tomography (ct) |
1 |
conditioning regimen |
1 |
conditioning regimen intensity |
1 |
cord blood |
1 |
cx3cr1 |
1 |
cy |
1 |
cyclooxygenase-2 |
1 |
cytogenetics |
1 |
cytotoxicity |
1 |
defibrotide |
1 |
dli |
1 |
dna damage |
1 |
dyskeratosis congenita |
1 |
ebv |
1 |
encephalopathy |
1 |
engraftment |
1 |
engraftment syndrome |
1 |
enteral nutrition |
1 |
epstein-barr virus |
1 |
etv6-runx1 |
1 |
ewing sarcoma |
1 |
ewing's sarcoma |
1 |
ex vivo expansion |
1 |
exvivo expansion |
1 |
gd2 monoclonal antibody |
1 |
genetic association study |
1 |
good manufacturing practice (gmp) |
1 |
graft failure |
1 |
graft versus host disease |
1 |
graft-versus-host disease (gvhd) |
1 |
graft-versus-tumor |
1 |
graft-versus-tumor effect |
1 |
graft-vs-host disease |
1 |
gvhd |
1 |
haematological malignancy |
1 |
haematopoietic stem cell transplantation |
1 |
haploidentical donor |
1 |
haploidentical donors |
1 |
haploidentical haematopoietic stem cell transplantation |
1 |
haploidentical stem cell transplantation |
1 |
haploidentical transplantation |
1 |
healthcare providers preferences |
1 |
hematopoiesis |
1 |
hematopoietic cell transplantation |
1 |
hematopoietic stem cell transplant |
1 |
hematopoietic stem cell transplantation (hsct) |
1 |
hemophagocytic lymphohistiocytosis |
1 |
hepatic veno-occlusive disease |
1 |
hepatoblastoma |
1 |
hla |
1 |
hsct |
1 |
human |
1 |
human in utero transplantation |
1 |
human leucocyte antigen |
1 |
human leucocyte antigen (hla) |
1 |
human leukocyte antigen |
1 |
human nk cell |
1 |
hypodiploid acute lymphoblastic leukemia |
1 |
immunity |
1 |
immunization |
1 |
immunogenetics |
1 |
immunologic reconstitution after transplantation |
1 |
immunology |
1 |
immunophenotyping |
1 |
immunosuppressive therapy |
1 |
incidence |
1 |
infant all |
1 |
infant aml |
1 |
infant leukemia |
1 |
infection |
1 |
iron overload |
1 |
keratinocyte growth factor |
1 |
killer cell immunoglobulin-like receptor |
1 |
killer cell immunoglobulin-like receptors (kir) |
1 |
killer cells |
1 |
killer-cell immunoglobulin-like receptor |
1 |
killer-cell immunoglobulin-like receptor (kir) |
1 |
kir match |
1 |
kir mismatch |
1 |
kir polymorphism |
1 |
kir-hla mismatch |
1 |
kir2dl1 allelotyping |
1 |
kirs genotyping |
1 |
large-volume leukapheresis |
1 |
late effects |
1 |
late sequelae |
1 |
lentivirus |
1 |
leukaemia |
1 |
leukoencephalopathy |
1 |
long-term follow-up |
1 |
long-term survival |
1 |
lymphoblastic leukemia |
1 |
lymphodepletion |
1 |
lymphoma |
1 |
lymphopoiesis |
1 |
lymphoproliferative disorder |
1 |
lymphphoid malignancies |
1 |
malnutrition |
1 |
manufacturing |
1 |
manufacturing of nk cell products |
1 |
matched sibling donor |
1 |
melanoma |
1 |
memory t cells |
1 |
mice-scid |
1 |
microfluidic |
1 |
minimal residual disease |
1 |
mismatched transplantation |
1 |
mortality |
1 |
mrc aml12 |
1 |
multiple thresholds |
1 |
myelodysplastic syndromes |
1 |
natural killer |
1 |
natural killer (nk) cell |
1 |
natural killer cell |
1 |
nk cell |
1 |
nk cell proliferation |
1 |
nk cells bmt |
1 |
nkg2d-nkg2dl interactions |
1 |
nod/scid chimeras |
1 |
non-hodgkin lymphoma |
1 |
non-myeloablative |
1 |
nutrition |
1 |
nutrition support |
1 |
nutritional support |
1 |
opportunistic infection |
1 |
ordered logistic model |
1 |
osteonecrosis |
1 |
osteosarcoma tumor initiating cells |
1 |
parainfluenza virus |
1 |
parenteral nutrition |
1 |
pediatric bmfs |
1 |
pediatric disorders |
1 |
pediatric leukemia |
1 |
pediatric oncology |
1 |
pediatric soild tumor |
1 |
pediatric solid tumors |
1 |
pediatric transplant |
1 |
pediatric transplantation |
1 |
peripheral blood stem cells |
1 |
pharmacokinetics |
1 |
plerixafor |
1 |
pneumocystis carinii |
1 |
pneumonia |
1 |
post-transplant complications |
1 |
post-transplantation cyclophosphamide |
1 |
prognostic factor |
1 |
prognostic factors |
1 |
pulmonary function |
1 |
pulmonary toxicity |
1 |
quality control |
1 |
qutologous |
1 |
rabbit antithymocyte globulin (ratg) |
1 |
radiosurgery |
1 |
rare variants |
1 |
reduced intensity conditioning regimen |
1 |
reduced-intensity regimen |
1 |
reduced-intensity transplantation |
1 |
refractory |
1 |
rejection |
1 |
relapsed |
1 |
respiratory |
1 |
respiratory virus |
1 |
ric |
1 |
risk factors |
1 |
safety |
1 |
sarcoma |
1 |
second transplant |
1 |
secondary acute myeloid leukemia |
1 |
set-valued system identification |
1 |
severe combined immune deficiency |
1 |
sickle cell disease |
1 |
single nucleotide polymorphism (snp) assay |
1 |
single-nucleotide polymorphism |
1 |
solid tumour |
1 |
statistics |
1 |
stem cell transplant |
1 |
stem cells |
1 |
stool |
1 |
survivor |
1 |
t cell |
1 |
t cell depleted |
1 |
t cells |
1 |
t-cell all |
1 |
t-cell depletion |
1 |
t-cell homeostatic proliferation |
1 |
t-cell receptor beta cdr3 size spectratyping |
1 |
t-cell receptor excision circle |
1 |
tel-aml1 |
1 |
thalasssaemia |
1 |
therapy-related |
1 |
thymoglobulin |
1 |
thymopoiesis |
1 |
thymus |
1 |
topotecan |
1 |
total body irradiation |
1 |
toxicity |
1 |
transduction |
1 |
transplant |
1 |
transplant tolerance |
1 |
treatment era |
1 |
treatment failure |
1 |
tumor therapy |
1 |
xenogeneic stem cell transplantation |
1 |
xlp |
1 |